Celldex Therapeutics (CLDX)
NASDAQ:CLDX
Want to see CLDX full AI Analyst Report?
Total Valuation
Celldex has a market cap or net worth of $2.37B. The enterprise value is $2.02B.
Market Cap$2.37B
Enterprise Value$2.02B
Share Statistics
Celldex has 78,492,070 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding78,492,070
Owned by Insiders0.30%
Owned by Institutions38.21%
Financial Efficiency
Celldex’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -53.87%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-53.87%
Return on Capital Employed (ROCE)-0.54
Revenue Per Employee8.06K
Profits Per Employee-1.39M
Employee Count186
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Celldex is ―. Celldex’s PEG ratio is -0.12.
PE Ratio―
PS Ratio1204.09
PB Ratio3.43
Price to Fair Value3.43
Price to FCF-8.45
Price to Operating Cash Flow-9.26
PEG Ratio-0.12
Income Statement
In the last 12 months, Celldex had revenue of 1.50M and earned -258.80M in profits. Earnings per share was -3.90.
Revenue1.50M
Gross Profit1.50M
Operating Income-287.40M
Pretax Income-258.80M
Net Income-258.80M
EBITDA-255.42M
Earnings Per Share (EPS)-3.90
Cash Flow
In the last 12 months, operating cash flow was -222.16M and capital expenditures -3.80M, giving a free cash flow of -225.96M billion.
Operating Cash Flow-222.16M
Free Cash Flow-225.96M
Free Cash Flow per Share-2.88
Dividends & Yields
Celldex pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.25
52-Week Price Change54.89%
50-Day Moving Average32.07
200-Day Moving Average27.20
Relative Strength Index (RSI)42.64
Average Volume (3m)851.52K
Important Dates
Celldex upcoming earnings date is Aug 6, 2026, After Close (Confirmed).
Last Earnings DateMay 7, 2026
Next Earnings DateAug 6, 2026
Ex-Dividend Date―
Financial Position
Celldex as a current ratio of 10.49, with Debt / Equity ratio of 0.42%
Current Ratio10.49
Quick Ratio10.49
Debt to Market Cap<0.01
Net Debt to EBITDA0.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Celldex has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Celldex EV to EBITDA ratio is -6.97, with an EV/FCF ratio of -8.33.
EV to Sales1.19K
EV to EBITDA-6.97
EV to Free Cash Flow-8.33
EV to Operating Cash Flow-8.44
Balance Sheet
Celldex has $451.46M in cash and marketable securities with $1.91M in debt, giving a net cash position of $449.55M billion.
Cash & Marketable Securities$451.46M
Total Debt$1.91M
Net Cash$449.55M
Net Cash Per Share$5.73
Tangible Book Value Per Share$7.52
Margins
Gross margin is -4.15%, with operating margin of -19160.00%, and net profit margin of -17253.33%.
Gross Margin-4.15%
Operating Margin-19160.00%
Pretax Margin-17253.33%
Net Profit Margin-17253.33%
EBITDA Margin-17028.00%
EBIT Margin-17253.33%
Analyst Forecast
The average price target for Celldex is $56.73, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$56.73
Price Target Upside64.19% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast-88.54%
EPS Growth Forecast-58.13%